Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#80 of 589

Sudan Loganathan

Stephens & Co. · Equity Research Analyst
ProvisionalRating since 2024No new ratings since Nov 2025

Analyst rating accuracy & track record

Sudan Loganathan is an equity research analyst at Stephens & Co.. Quantellect has scored 25 of their stock calls across 12 companies. Their picks beat their sector 47% of the time over the next 12 months, and their price targets were reached 25% of the time within a year.

Win % vs sector
47%
PT Hit % (12mo)
25%
Avg sector-excess
+4.0%
Scored calls
25
Tickers
12
Tier
Provisional

Track record

Quantellect has scored 25 of Sudan Loganathan's stock calls across 12 companies, dating back to 2024. Their rated stocks beat their own sector 47% of the time over the next 12 months. On a typical call, a Loganathan pick returned +4.0% more than its sector over the following year.

Of the scored calls, 25 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
ARVNArvinas Inc
Buy$15.00Nov 2025−64.7%Miss
DCTHDelcath Systems Inc
Buy$18.00Nov 2025+39.9%Miss
CADLCandel Therapeutics Inc
Buy$15.00Oct 2025+32.1%Miss
CADLCandel Therapeutics Inc
Buy$15.00Oct 2025+32.1%Miss
CCCCC4 Therapeutics Inc
Buy$6.00Sep 2025+2.7%Miss
ARVNArvinas Inc
Buy$14.00Sep 2025−13.5%Hit
CCCCC4 Therapeutics Inc
Buy$6.00Sep 2025−23.0%Miss
CCCCC4 Therapeutics Inc
Buy$6.00Sep 2025−23.0%Miss
IDYAIdeaya Biosciences Inc
Buy$45.00Sep 2025+32.3%Miss
SNSESensei Biotherapeutics Inc
Buy$35.00Jun 2025+164.9%Hit
DCTHDelcath Systems Inc
Buy$25.00Jun 2025−26.6%Miss
IMNMImmunome Inc
Buy$30.00Mar 2025+143.7%Miss
CPRXCatalyst Pharmaceuticals Inc
Buy$33.00Feb 2025−8.6%Miss
ADCTADC Therapeutics SA
Buy$8.00Feb 2025+173.5%Miss
ATNMActinium Pharmaceuticals Inc
Buy$5.00Nov 2024−10.7%Miss
CPRXCatalyst Pharmaceuticals Inc
Buy$35.00Nov 2024−4.1%Miss
PYXSPyxis Oncology Inc
Buy$13.00Nov 2024+0.2%Miss
IMNMImmunome Inc
Buy$30.00Nov 2024+23.6%Miss
ADCTADC Therapeutics SA
Buy$6.00Nov 2024+40.9%Miss
DCTHDelcath Systems Inc
Buy$25.00Aug 2024+45.7%Miss
SNSESensei Biotherapeutics Inc
Buy$5.00May 2024−56.9%Miss
INOInovio Pharmaceuticals Inc
Buy$20.00May 2024−75.1%Miss
SNSESensei Biotherapeutics Inc
Buy$5.00May 2024−66.7%Miss
DCTHDelcath Systems Inc
Buy$25.00May 2024+125.7%Miss
ATNMActinium Pharmaceuticals Inc
Buy$25.00May 2024−74.5%Miss
Prev1Next
Go to

Sudan Loganathan: analyst track record FAQ

Is Sudan Loganathan a good stock analyst?

Yes, by track record. Sudan Loganathan ranks number 80 of 589 of the analysts Quantellect scores, with an Analyst Score of 62 out of 100. Past results do not guarantee future ones.

What is Sudan Loganathan's win rate?

Sudan Loganathan's win rate is 47%. Across 25 scored calls, their rated stocks beat their sector 47% of the time over the next 12 months. On a typical call they returned +4.0% more than the sector.

What stocks and sectors does Sudan Loganathan cover?

Sudan Loganathan covers 12 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Sudan Loganathan's price targets accurate?

Sudan Loganathan's price targets are reached within 12 months 25% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Sudan Loganathan's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Sudan Loganathan rank among Wall Street analysts?

Sudan Loganathan ranks number 80 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.